HR Execs on the Move

Mango Materials

www.mangomaterials.com

 
Mango Materials produces biodegradable plastics from waste biogas (methane) that are economically competitive with conventional, oil-based plastics. Mango Materials produces poly-hydroxyalkanoate (PHA) powder, a valuable biopolymer that is converted into a variety of ecofriendly, plastic products such as children’s toys, electronic casings, water bottles, and food packaging containers. Due to a rising preference for green products, demand for biodegradable and non petroleum-based plastics is growing rapidly. Mango Materials uses affordable methane gas and a process that competes favorably with petroleum-based plastics to produce low-cost, biodegradable plastics.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Elizabeth Thompson
 Vice President, People Profile

Similar Companies

Walter Payton Cancer Fund

Walter Payton Cancer Fund is a Schaumburg, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nashai

Nashai is a Nashville, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hollister-Stier Laboratories

Hollister-Stier Laboratories is a Spokane, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HyperOmics Farma

HyperOmics Farma Inc. is a Montr��al, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Juventas Therapeutics

Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.